Draft Recommendation Statement and Draft Evidence Review: Pre-Exposure Prophylaxis for the Prevention of HIV Infection - US Preventive Services Task Force

Opportunity for Public Comment - US Preventive Services Task Force

Draft Recommendation Statement and Draft Evidence Review: Pre-Exposure Prophylaxis for the Prevention of HIV Infection

Public Comment on Draft Recommendation Statement and Draft Evidence Review: Pre-Exposure Prophylaxis for the Prevention of HIV Infection The U.S. Preventive Services Task Force seeks comments on a draft recommendation statement and draft evidence review on pre-exposure prophylaxis (PrEP) for the prevention of HIV infection. The Task Force found that clinicians should offer PrEP to people at high risk for HIV. The draft recommendation statement and draft evidence review are available for review and public comment from November 20, 2018 to December 26, 2018 here. The Draft Recommendation Statement and Draft Evidence Review Are Open to Public Comment

COMMENTING DETAILS

Public Comment Period: 11/20/18-12/26/18 Any visitor to the Task Force Web site can comment on any of the listed USPSTF draft documents. However, readers should note that the USPSTF writes these documents for researchers, primary care doctors, and other health care providers, using medical and scientific language as appropriate for these audiences.

DRAFT RECOMMENDATION SUMMARY

Population Recommendation Grade Persons at high risk of HIV acquisition The USPSTF recommends that clinicians offer pre-exposure prophylaxis (PrEP) with effective antiretroviral therapy to persons who are at high risk of HIV acquisition. A

See the full draft recommendation statement

WHERE WE ARE IN THE PROCESS

Draft Research Plan Final Research Plan Draft Recommendation / Draft Evidence Review Final Recommendation / Evidence Summary